2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
Event Sep 19 - Sep 20, 2019
The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years. After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.